{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:35:34Z","timestamp":1780590934205,"version":"3.54.1"},"reference-count":17,"publisher":"Codon Publications","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergologia et Immunopathologia"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.aller.2013.11.007","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T02:30:12Z","timestamp":1397442612000},"page":"168-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria"],"prefix":"10.15586","volume":"43","author":[{"given":"P.M.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6228","reference":[{"key":"10.1016\/j.aller.2013.11.007_bib0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1398-9995.2009.02179.x","article-title":"EAACI\/GA2LEN\/EDF\/WAO guideline: definition, classification and diagnosis of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.aller.2013.11.007_bib0010","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1398-9995.2008.01920.x","article-title":"The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings","volume":"64","author":"Mlynek","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.aller.2013.11.007_bib0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/all.12056","article-title":"EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria","volume":"68","author":"Konstantinou","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.aller.2013.11.007_bib0020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","article-title":"EAACI\/GA2LEN\/EDF\/WAO guideline: management of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.aller.2013.11.007_bib0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1081-1206(10)60644-8","article-title":"Effect of omalizumab on patients with chronic urticaria","volume":"99","author":"Spector","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0040","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aller.2013.11.007_bib0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticarial despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1398-9995.2008.01726.x","article-title":"How to assess disease activity in patients with chronic urticaria?","volume":"63","author":"Mynek","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.aller.2013.11.007_bib0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1398-9995.2010.02472.x","article-title":"Omalizumab \u2013 an effective and safe treatment of therapy resistant chronic spontaneous urticaria","volume":"66","author":"Groffik","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.aller.2013.11.007_bib0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/ACI.0b013e328355365a","article-title":"Omalizumab in chronic urticaria","volume":"12","author":"Metz","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.anai.2012.11.022","article-title":"Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria","volume":"110","author":"Song","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000250436","article-title":"Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy","volume":"151","author":"Oliver","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.anai.2009.11.017","article-title":"Maintenance of remission with low-dose omalizumab in long-lasting, refractory chronic urticaria","volume":"104","author":"Romano","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.aller.2013.11.007_bib0085","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jaci.2010.12.1085","article-title":"Omalizumab is effective in nonautoimmune urticaria","volume":"127","author":"Ferrer","year":"2011","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergologia et Immunopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054614000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054614000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T22:49:52Z","timestamp":1609454992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301054614000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0301054614000299"],"URL":"https:\/\/doi.org\/10.1016\/j.aller.2013.11.007","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria","name":"articletitle","label":"Article Title"},{"value":"Allergologia et Immunopathologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aller.2013.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 SEICAP. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}